Aby J. Mathew Sells 17,604 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 17,604 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $20.05, for a total value of $352,960.20. Following the completion of the sale, the executive vice president now directly owns 284,442 shares in the company, valued at approximately $5,703,062.10. This represents a 5.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

BioLife Solutions Trading Up 9.6 %

BLFS stock traded up $1.97 during midday trading on Tuesday, reaching $22.44. The company’s stock had a trading volume of 713,055 shares, compared to its average volume of 382,708. The business’s 50-day simple moving average is $23.94 and its 200-day simple moving average is $22.84. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 52 week low of $11.91 and a 52 week high of $28.88. The stock has a market cap of $1.04 billion, a PE ratio of -21.17 and a beta of 1.88.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. HC Wainwright cut their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday. Northland Securities increased their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Craig Hallum boosted their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, TD Cowen increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $27.50.

Institutional Investors Weigh In On BioLife Solutions

A number of institutional investors have recently made changes to their positions in BLFS. Vanguard Group Inc. lifted its stake in BioLife Solutions by 11.5% in the first quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock valued at $53,208,000 after buying an additional 296,727 shares during the period. Fred Alger Management LLC increased its stake in shares of BioLife Solutions by 6.0% in the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after acquiring an additional 88,840 shares during the last quarter. State Street Corp raised its position in shares of BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after acquiring an additional 95,788 shares during the period. Geode Capital Management LLC boosted its stake in BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after acquiring an additional 18,473 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in BioLife Solutions by 9.1% during the second quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock valued at $17,034,000 after purchasing an additional 66,422 shares during the period. 93.24% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.